Laigo Bio, a Netherlands-based biotech company specializing in targeted protein degradation therapies, has successfully closed an oversubscribed seed financing round, raising a total of €17 million. The latest funding, which includes €4 million from new lead investor Biovance Capital, will bolster the development of Laigo’s proprietary SureTACs platform. This technology aims to create bispecific antibodies to selectively degrade disease-causing membrane proteins, with a focus on oncology and autoimmune conditions. The funds will expedite clinical development of oncology programs and advance candidate programs targeting immunology disorders. The company has attracted backing from notable investors, including Kurma Partners and Biovance Capital.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://pulse2.com/laigo-bio-e17-million-raised-for-biotech-developing-suretacs-precision-protein-degradation-platform/
